CSL Limited trades at a decade-low P/E, despite ongoing revenue and profit growth, presenting significant upside potential. Learn more about CMXHF stock here.

Fintel reports that on December 8, 2025, JEFFERIES maintained coverage of CSL Limited - Depositary Receipt (OTCPK:CSLLY) with a Buy recommendation. As of December 6, 2025, the average one-year price ...

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with CSL Limited Sponsored ADR (CSLLY) ...

A leading investment expert forecasts a stronger year ahead for CSL shares. Let’s see why. The post 3 reasons to buy CSL ...

Here's updated analysis on three of Australia's largest healthcare stocks. The post What can investors expect from ResMed, ...

The modest increase in CSL shares stands out against the backdrop of a declining local market, where the S&P/ASX 200 fell 0.66% to 8,815.9. RBC's decision to upgrade CSL comes after a significant 36% ...

CSL Ltd. plunged to the lowest in almost seven years after Australia’s biggest drugmaker postponed plans to spin off its vaccines business, as falling US flu immunizations deepen concern over a ...

CSL Ltd.’s stock tumbled 16.88% on the news that it plans to cut 3,000 jobs and to hive off its Seqirus vaccine unit in a cost-cutting measure to save more than $500 million per year over the next ...

CSL Ltd., the world’s second-biggest maker of flu shots, forecast a US vaccination rebound as health groups counter misinformation and rising illness rates revive concern about prevention. A recovery ...

Australian biotechnology firm CSL Ltd (OTCQX:CSLLY) (OTCQX:CMXHF) is set to downsize its research and development (R&D) division across six international sites, and increase its reliance on external ...